# Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

> **NCT02581943** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 43 (actual)

## Conditions studied

- Recurrent Non-Small Cell Lung Carcinoma
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02581943
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-17
- **Primary completion:** 2022-11-19
- **Final completion:** 2022-12-28
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581943, "Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02581943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*